Cyclophosphamide versus placebo in scleroderma lung disease

Donald P. Tashkin, Robert Elashoff, Philip J. Clements, Jonathan Goldin, Michael D. Roth, Daniel E. Furst, Edgar Arriola, Richard Silver, Charlie Strange, Marcy Bolster, James R. Seibold, David J. Riley, Vivien M. Hsu, John Varga, Dean E. Schraufnagel, Arthur Theodore, Robert Simms, Robert Wise, Fredrick Wigley, Barbara WhiteVirginia Steen, Charles Read, Maureen Mayes, Ed Parsley, Kamal Mubarak, M. Kari Connolly, Jeffrey Golden, Mitchell Olman, Barri Fessler, Naomi Rothfield, Mark Metersky

Research output: Contribution to journalArticle

1017 Scopus citations

Abstract

BACKGROUND: We conducted a double-blind, randomized, placebo-controlled trial to determine the effects of oral cyclophosphamide on lung function and health-related symptoms in patients with evidence of active alveolitis and scleroderma-related interstitial lung disease. METHODS: At 13 clinical centers throughout the United States, we enrolled 158 patients with scleroderma, restrictive lung physiology, dyspnea, and evidence of inflammatory interstitial lung disease on examination of bronchoalveolar-lavage fluid, thoracic highresolution computed tomography, or both. Patients received oral cyclophosphamide (≤2 mg per kilogram of body weight per day) or matching placebo for one year and were followed for an additional year. Pulmonary function was assessed every three months during the first year, and the primary end point was the forced vital capacity (FVC, expressed as a percentage of the predicted value) at 12 months, after adjustment for the baseline FVC. RESULTS: Of 158 patients, 145 completed at least six months of treatment and were included in the analysis. The mean absolute difference in adjusted 12-month FVC percent predicted between the cyclophosphamide and placebo groups was 2.53 percent (95 percent confidence interval, 0.28 to 4.79 percent), favoring cyclophosphamide (P<0.03). There were also treatment-related differences in physiological and symptom outcomes, and the difference in FVC was maintained at 24 months. There was a greater frequency of adverse events in the cyclophosphamide group, but the difference between the two groups in the number of serious adverse events was not significant. CONCLUSIONS: One year of oral cyclophosphamide in patients with symptomatic sclerodermarelated interstitial lung disease had a significant but modest beneficial effect on lung function, dyspnea, thickening of the skin, and the health-related quality of life. The effects on lung function were maintained through the 24 months of the study.

Original languageEnglish (US)
Pages (from-to)2655-2666
Number of pages12
JournalNew England Journal of Medicine
Volume354
Issue number25
DOIs
StatePublished - Jun 22 2006

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint Dive into the research topics of 'Cyclophosphamide versus placebo in scleroderma lung disease'. Together they form a unique fingerprint.

  • Cite this

    Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., Arriola, E., Silver, R., Strange, C., Bolster, M., Seibold, J. R., Riley, D. J., Hsu, V. M., Varga, J., Schraufnagel, D. E., Theodore, A., Simms, R., Wise, R., Wigley, F., ... Metersky, M. (2006). Cyclophosphamide versus placebo in scleroderma lung disease. New England Journal of Medicine, 354(25), 2655-2666. https://doi.org/10.1056/NEJMoa055120